SIGA Q1 revenue doubles to $10.5M; net loss narrows; declares special $0.45 dividend

SIGA TECHNOLOGIES INC

2022-Q1 EPS reported -$0.01 revenue$10,539,299

Q1 total revenues $10.5M vs $4.8M YoY; operating loss improved to $1.4M from $2.0M.
First IV TPOXX sales to U.S. govt under BARDA contract: $7M delivered in Q1.
New Asia Pacific contract for ~$3M of oral TPOXX; PHAC contract increased $5M.
Board declared special dividend of $0.45/share, payable June 2 to holders of record May 17.
EMA approved oral tecovirimat for smallpox, monkeypox, cowpox, and vaccinia complications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.